Table 1. Adverse Events and Laboratory Abnormalities Reported in ≥ 20% of Subjects.

	PLD + motolimod n = 13		paclitaxel + motolimod n = 7
Adverse Event	All Grades n (%)	Grade 3/4 n (%)	All Grades n (%)	Grade 3/4 n (%)
Abdominal pain	7 (54)	2 (15)	3 (49)	0 (0)
Alopecia	3 (23)	0 (0)	2 (29)	0 (0)
Anemia	10 (77)	2 (15)	7 (100)	0 (0)
Anorexia	6 (46)	0 (0)	1 (14)	0 (0)
Anxiety	3 (23)	0 (0)	1 (14)	0 (0)
Arthralgia	6 (46)	0 (0)	3 (43)	0 (0)
Back pain	5 (39)	0 (0)	0 (0)	0 (0)
Chills	9 (69)	1 (8)	3 (49)	0 (0)
Constipation	7 (54)	0 (0)	2 (29)	0 (0)
Cough	3 (23)	1 (8)	2 (29)	0 (0)
Diarrhea	5 (39)	0 (0)	4 (57)	1 (14)
Dyspnea	4 (31)	1 (8)	3 (43)	0 (0)
Fatigue	13 (100)	0 (0)	7 (100)	1 (14)
Fever	11 (85)	1 (8)	3 (43)	0 (0)
Headache	9 (69)	0 (0)	1 (14)	0 (0)
Hypertension	4 (31)	1 (8)	1 (14)	1 (14)
Injection site reaction	12 (92)	0 (0)	5 (71)	0 (0)
Mucositis oral	7 (54)	2 (15)	0 (0)	0 (0)
Myalgia	2 (15)	0 (0)	2 (29)	0 (0)
Nausea	10 (77)	1 (8)	4 (57)	0 (0)
Palmar-plantar erythrodysesthesia syndrome	4 (31)	1 (8)	0 (0)	0 (0)
Paresthesia	4 (31)	0 (0)	0 (0.0)	0 (0)
Peripheral sensory neuropathy	6 (46)	0 (0)	4 (57)	0 (0)
Vomiting	10 (77)	2 (15)	5 (71)	0 (0)
Weight loss	2 (15)	0 (0)	2 (29)	0 (0)
Laboratory Abnormality
Hypoalbuminemia	3 (23)	2 (15)	2 (29)	0 (0)
Hypokalemia	2 (15)	1 (8)	2 (29)	0 (0)
Hyponatremia	2 (15)	1 (8)	2 (29)	1 (14)
Platelet count decreased	4 (31)	1 (8)	0 (0)	0 (0)
Neutrophil count decreased	8 (62)	3 (23)	1 (14)	1 (14)
White blood cell decreased	8 (62)	1 (8)	1 (14)	1 (14)

Adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE).